News

Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today…
Read More...

Gilead Sciences, Inc. announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for…
Read More...

Bayer has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for darolutamide for the treatment of patients with non-metastatic…
Read More...

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority Review. Fedratinib…
Read More...

Beam Therapeutics announced the successful completion of a $135 million Series B financing. Proceeds from the financing will be used to advance the company’s development of…
Read More...

Domainex is pleased to announce that a team of its scientists, working in close partnership with Professor Michael Schneider and his team at Imperial College, have found a potential new…
Read More...

GTx, Inc. and Oncternal Therapeutics, Inc. jointly announced that they have entered into a definitive merger agreement under which the stockholders of Oncternal would become the…
Read More...

Sartorius Stedim Biotech (SSB) and Novasep based in Pompey, France, have entered into a collaboration agreement in the area of chromatography and single-use bioprocessing. Novasep…
Read More...

Vertex Pharmaceuticals Incorporated announced that treatment with the triple combination of the next-generation corrector VX-445, tezacaftor and ivacaftor resulted in statistically…
Read More...

NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, has closed a Series A financing round of CHF 10…
Read More...

Scientists from the Hubrecht Institute, the University of Utrecht, and MIMETAS have successfully grown kidney tubules derived from human kidney adult stem cells in microfluidic chips.…
Read More...

Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for LORVIQUA (lorlatinib, approved…
Read More...

Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The…
Read More...

Pacira Pharmaceuticals and MyoScience announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira. MyoScience currently markets the ioveraº system, a…
Read More...

ReForm Biologics announced a collaboration with Astellas Pharma Inc. to reduce the viscosity of an Astellas clinical-stage biological pipeline program. Reform’s technology platform…
Read More...

Bayer has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) in Japan for darolutamide for the treatment of patients with…
Read More...

AnTolRx announced that Pfizer Inc. has exercised the option granted under a June 2016 agreement to license an immune tolerance therapy from AnTolRx's Type 1 diabetes research program.…
Read More...

Nichi-Iko Pharmaceutical Co., Ltd. and Sagent Pharmaceuticals, Inc., a Nichi-Iko Group Company announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North…
Read More...

Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the…
Read More...

Medexus Pharmaceuticals Inc. announced that it has entered into a licensing agreement with photonamic GmbH & Co. KG for the exclusive rights to market and distribute Gliolan in…
Read More...